Candel Therapeutics, Inc.

Informe acción NasdaqGM:CADL

Capitalización de mercado: US$679.2m

Candel Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Candel Therapeutics es Paul-Peter Tak , nombrado en Sep 2020, tiene una permanencia de 5.75 años. compensación anual total es $4.95M, compuesta por 15% salario y 85% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de $2.49M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 6.7 años, respectivamente.

Información clave

Paul-Peter Tak

Chief Executive Officer (CEO)

US$4.9m

Compensación total

Porcentaje del salario del CEO15.03%
Permanencia del CEO5.8yrs
Participación del CEO0.4%
Permanencia media de la dirección4.3yrs
Promedio de permanencia en la Junta Directiva6.7yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Apr 21

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Summary Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene. CADL’s robust cash position funds operations into Q1 2028, but commercial execution and payer adoption remain critical risks to monitor post-approval. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Candel Therapeutics: Entering Its Pivotal Year

Summary Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. Big risks remain due to its negative EPS and debt ratios, but that potential FDA approval and its varied proprietary platforms make Candel an attractive acquisition target. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Summary Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. Viral therapies like CAN-2409 face commercialization challenges, but the strong phase 3 data justifies maintaining a "Buy" rating for CADL stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 01

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Summary Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells. Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers. CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer. Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion. The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024. Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409. Read the full article on Seeking Alpha
Seeking Alpha • Sep 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the treatment of glioma, which is a type of tumor that occurs in the brain and spinal cord. The European Medicines Agency's (EMA) Committee for Orphan Medical Products issued the positive opinion, CADL said in a statement. CAN-2409 is a genetically modified adenovirus that is currently being evaluated in multiple phase 2 and 3 trials for lung, brain, pancreatic and prostate cancers, CADL said. The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases. CADL said the orphan drug designation follows a U.S. FDA fast track designation granted in June last year for CAN-2409 to be used in combination with antiviral drug valacyclovir to treat newly diagnosed glioma. CADL stock +3.7% to $3.64 in early trading.
Seeking Alpha • Sep 07

Candel Therapeutics appoints CFO, chief medical officer

Biopharmaceutical company Candel Therapeutics (NASDAQ:CADL) appointed Jason Amello CFO and Garrett Nichols chief medical officer. Amello, whose appointment is effective Sep. 21, is replacing John Canepa. Canepa has decided to pursue other interests and spend more time with his family. Amello joins from the rare disease biotech company Saniona, while Nichols joins from Istari Oncology. Source: Press Release
Seeking Alpha • Oct 21

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer. CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer. With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel. Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul-Peter Tak en comparación con los beneficios de Candel Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$54m

Dec 31 2025US$5mUS$744k

-US$38m

Sep 30 2025n/an/a

-US$23m

Jun 30 2025n/an/a

-US$22m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$1mUS$689k

-US$55m

Sep 30 2024n/an/a

-US$52m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$1mUS$670k

-US$38m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$2mUS$670k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$957kUS$545k

-US$36m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$135k

-US$18m

Compensación vs. Mercado: La compensación total de Paul-Peter($USD4.95M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.69M).

Compensación vs. Ingresos: La compensación de Paul-Peter ha aumentado mientras la empresa no es rentable.

CEO

Paul-Peter Tak (66 yo)

5.8yrs
Permanencia
US$4,947,909
Compensación

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Paul-Peter Tak
President5.8yrsUS$4.95m0.37%
$ 2.5m
Charles Schoch
Senior VP2.4yrsUS$1.24m0.059%
$ 402.2k
Francesca Barone
Chief Scientific Officer4.3yrsUS$1.36m0.14%
$ 934.5k
Seshu Tyagarajan
Chief Technical & Development Officer4.2yrsUS$613.23k0.12%
$ 842.3k
Ileen Winick
Chief People Officerno datasin datossin datos
Susan Stewart
Chief Regulatory Officer5.7yrssin datossin datos
William Garrett
Chief Medical Officer3.8yrssin datos0.072%
$ 486.6k
4.3yrs
Permanencia media
57.5yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de CADL se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Paul-Peter Tak
President5.8yrsUS$4.95m0.37%
$ 2.5m
Edward Benz
Member of Research Advisory Board & Independent Director8.8yrsUS$103.55k0%
$ 0
Paul Manning
Independent Chairman7.6yrsUS$130.55k6.07%
$ 41.2m
Scott Eggener
Member of Scientific Advisory Boardno datasin datossin datos
Adam Kibel
Member of Scientific Advisory Boardno datasin datossin datos
E. Chiocca
Member of Scientific Advisory Boardno datasin datossin datos
Renee Gaeta
Independent Director3.8yrsUS$103.05k0%
$ 0
Christopher Martell
Independent Director7.6yrsUS$114.55k1.01%
$ 6.9m
Charu Aggarwal
Member of Scientific Advisory Boardno datasin datossin datos
Steven Albelda
Member of Scientific Advisory Boardno datasin datossin datos
Mark Bloomston
Member of Scientific Advisory Boardno datasin datossin datos
Nicoletta Loggia
Independent Director3yrsUS$107.02k0.0029%
$ 19.8k
6.7yrs
Permanencia media
62yo
Promedio de edad

Junta con experiencia: La junta directiva de CADL se considera experimentada (6.7 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/06/25 11:55
Precio de las acciones al final del día2026/06/25 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Candel Therapeutics, Inc. está cubierta por 10 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets